All Oncology News

Benjamin P. Levy, MD, highlights the pros and cons of the different platforms for circulating tumor DNA detection, as well as the benefits and limitations of liquid biopsies.

Yelena Novik, MD, discusses the application of CDK4/6 inhibition and methods to overcome resistance in ER-positive breast cancer.

The Centers for Medicare & Medicaid Services has proposed a slate of changes that would reduce payment for some forms of patient evaluation and management and reduce the payment margin over wholesale acquisition cost for Medicare Part B drugs.

The FDA has approved enzalutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer.

Ami Vijay Desai, MD, discusses the ideal patient population for entrectinib and what the future could hold for the agent.

Hans-Christian Kolberg, MD, discusses ABP 980 and the future of biosimilars in oncology.

Paul Richardson, MD, discusses the efficacy and tolerability of the combination of pomalidomide (Pomalyst), bortezomib (Velcade), and dexamethasone in patients with multiple myeloma.

Matthew Galsky, MD, discusses the IMvigor130 and CheckMate-901 studies, as well as the future for chemotherapy in bladder cancer.

Liza C. Villaruz, MD, addresses the immunotherapy clinical trials that have informed the treatment of patients with NSCLC and the current state of biomarkers in the field.

Charles G. Drake, MD, PhD, discusses the importance of the CARMENA results, the future of cytoreductive nephrectomy, and how the use of immunotherapy could change treatment in this setting.

Michael Wang, MD, discusses what he hopes to find in the ZUMA-2 trial and his belief that MCL can be cured in his lifetime.

Deborah Krakow, MD, discusses the value of a patient’s family history and its implications on genetic counseling.

Santhosh A. Upadhyaya, MD, discusses how chemotherapy prior to radiation can improve cure rates, the importance of long-term follow-up in this patient population, and emerging research and treatment for pediatric ependymoma.

A supplemental New Drug Application has been submitted to the FDA for venetoclax (Venclexta) for use in combination with a hypomethylating agent or low-dose cytarabine for the first-line treatment of patients with acute myeloid leukemia.

Christopher J. Pietras, MD, discusses the elements of palliative care for patients with ovarian cancer.

The FDA has granted a priority review designation to a supplemental biologics license application for pembrolizumab for previously treated patients with advanced hepatocellular carcinoma

Sanaz Memarzadeh, MD, PhD, details the early developments of antibody-directed therapies and restoring p53 function in the treatment of patients with ovarian cancer.

Combining ibrutinib with standard R-CHOP did not improve event-free survival versus R-CHOP alone in the first-line setting for patients with diffuse large B-cell lymphoma.

Ixazomib (Ninlaro) improved progression-free survival compared with placebo as a maintenance therapy in adult patients with multiple myeloma who responded to high-dose therapy and autologous stem cell transplant.

Gottfried E. Konecny, MD, discusses developments in the understanding of response to PARP inhibition in ovarian cancer.

The FDA has approved the combination of nivolumab and ipilimumab for the treatment of adult and pediatric patients 12 years and older with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer following progression on a fluoropyrimidine, oxaliplatin, and irinotecan.

Progression-free survival appears to be a surrogate endpoint for overall survival in patients undergoing first-line treatment for diffuse large B-cell lymphoma, according to results from a large pooled analysis.

John A. Glaspy, MD, discusses challenges and progress with immunotherapy in gynecologic cancers.

Maryann J. Kwa, MD, discusses the optimal duration of endocrine therapy in the treatment of patients with early-stage ER-positive breast cancer.

Joshua Bauml, MD, discusses the limitations of PD-L1 and tumor mutational burden as immunotherapy biomarkers in non–small cell lung cancer and emerging biomarkers showing promise in the field.

Evan Ya-Wen Yu, MD, discusses the evolution of treatment for patients with castration-sensitive prostate cancer and how he decides between treatment with abiraterone and docetaxel for this population.

The combination of the CDK4/6 inhibitor palbociclib and cetuximab induced an overall response rate of 39% in patients with platinum-resistant, HPV-unrelated recurrent/metastatic head and neck squamous cell carcinoma.

Brock O’Neil, MD, discusses the struggles with treating localized bladder cancer in both the neoadjuvant and adjuvant settings, as well as the advancements with robotic cystectomy.

Michael A. Savin, MD, shares his insight on adjuvant endocrine therapy for premenopausal women with hormone receptor-positive breast cancer.

Alex E. Denes, MD, discusses the mixed results looking at the optimal duration of adjuvant endocrine therapy in postmenopausal women with breast cancer.